Abzena plc
Exercise of options
Total voting rights
Following the issue of the 672,980 new Ordinary Shares as set out above, the Company's issued share capital comprises 214,893,379 Ordinary Shares with voting rights. No Ordinary Shares are held in treasury. The total number of voting rights in the Company is therefore 214,893,379. This figure of 214,893,379 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
|
Director |
New Ordinary Shares resulting from option exercises |
Direct and indirect interest in Ordinary Shares1 |
% of issued share capital1 |
|
John Burt |
151,673 |
2,302,238 |
1.1% |
|
Julian Smith |
83,253 |
608,672 |
0.3% |
1 As enlarged by the issue of 672,980 new Ordinary Shares pursuant to the option exercise.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities/person closely associate
|
1(a) |
Name |
John Burt |
|
1(b) |
Position / Status |
Chief Executive Officer |
2 Reason for the Notification
|
2(a) |
Reason |
Exercise of Stock Options |
|
2(b) |
Initial notification / amendment |
Initial |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
3(a) |
Name |
Abzena plc |
|
3(b) |
Legal Entity Identifier ("LEI") |
213800SB5JV4O28JRM14 |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
4(a) |
Description of the financial instrument, type of instrument
|
Abzena plc ordinary shares of |
|
|
|
Identification code
|
GB00BN65QN46 |
|
|
4(b) |
Nature of transaction |
Exercise of 151,673 stock options
|
|
|
4(c) |
Price(s) and volumes(s) |
Price |
Volume |
|
|
|
(exercise price) |
151,673
|
|
4(d) |
Aggregated information |
Price |
Volume |
|
|
|
(exercise price) |
151,673
|
|
4(e) |
Date of transaction |
10 October 2018
|
|
|
4(f) |
Place of the transaction |
N/a
|
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities/person closely associate
|
1(a) |
Name |
Julian Smith |
|
1(b) |
Position / Status |
Director |
2 Reason for the Notification
|
2(a) |
Reason |
Exercise of Stock Options |
|
2(b) |
Initial notification / amendment |
Initial |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
3(a) |
Name |
Abzena plc |
|
3(b) |
Legal Entity Identifier ("LEI") |
213800SB5JV4O28JRM14 |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
4(a) |
Description of the financial instrument, type of instrument
|
Abzena plc ordinary shares of |
|
|
|
Identification code
|
GB00BN65QN46 |
|
|
4(b) |
Nature of transaction |
Exercise of 83,253 stock options
|
|
|
4(c) |
Price(s) and volumes(s) |
Price |
Volume |
|
|
|
(exercise price) |
83,253 |
|
4(d) |
Aggregated information |
Price |
Volume |
|
|
|
(exercise price) |
83,253 |
|
4(e) |
Date of transaction |
10 October 2018
|
|
|
4(f) |
Place of the transaction |
N/a
|
|
-Ends-
Enquiries:
|
Abzena plc John Burt, Chief Executive Officer
|
+44 1223 903498 |
|
N+1 Singer (Nomad & Broker) Aubrey Powell / Ben Farrow
|
+44 20 7496 3000 |
|
Instinctif Partners Melanie Toyne Sewell / Rozi Morris / Alex Shaw
|
+44 20 7457 2020 |
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.
Abzena offers the following services and technologies across its principal sites in
· Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;
· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
· Cell line development for the manufacture of recombinant proteins and antibodies;
· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
· Proprietary site-specific conjugation technologies and novel payloads for ADC development;
· GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and
· GMP analytical services for biopharmaceutical manufacturing projects.
For more information, please see www.abzena.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the